{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:29:28Z","timestamp":1768271368779,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chongqing Health Commission and Chongqing Science and Technology Commission","award":["2020FYYX040"],"award-info":[{"award-number":["2020FYYX040"]}]},{"name":"the First Batch of Key Disciplines on Public Health in Chongqing"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60\u201389 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV\u2009+\u2009bOPV, 2wIPV\u2009+\u2009bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96\u2013384, <jats:italic>P<\/jats:italic>&lt;0.05) than the \u201c2IPV\u2009+\u2009bOPV\u201d group. While the \u201c2IPV\u2009+\u2009bOPV\u201d group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768\u20132048, <jats:italic>P<\/jats:italic>&lt;0.05)and type 3 (Median:2048, QR: 512\u20132048, <jats:italic>P<\/jats:italic>&lt;0.05) than the IPV-only group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09389-8","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:02:08Z","timestamp":1716886928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiawei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenge","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"9389_CR1","unstructured":"Estivariz CF et al. Chapter 18: Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases, a.k.a. The Pink Book[M]. 14. Centers for Disease Control and Prevention, United States of America, 2021."},{"key":"9389_CR2","unstructured":"WHO. Poliomyelitis (polio)[EB\/OL]. https:\/\/www.who.int\/health-topics\/poliomyelitis#tab=tab_1."},{"key":"9389_CR3","unstructured":"Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013\u20132018[EB\/OL]. https:\/\/polioeradication.org\/who-we-are\/strategic-plan-2013-2018\/."},{"key":"9389_CR4","unstructured":"Agency Of Disease Control And Prevention. Vaccination work specifications[EB\/OL]. (2016-12-29)http:\/\/www.nhc.gov.cn\/cms-search\/xxgk\/getManuscriptXxgk.htm?id=8033406a995d460f894cb4c0331cb400."},{"issue":"97","key":"9389_CR5","first-page":"277","volume":"25","author":"WHO","year":"2022","unstructured":"WHO. Polio vaccines: WHO position paper \u2013 June 2022[J]. Wkly Epidemiol Rec. 2022;25(97):277\u2013300.","journal-title":"Wkly Epidemiol Rec"},{"issue":"6489","key":"9389_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.aba1238","volume":"368","author":"GR Macklin","year":"2020","unstructured":"Macklin GR, O\u2019Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine[J]. Science. 2020;368(6489):401\u20135.","journal-title":"Science"},{"issue":"2","key":"9389_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","volume":"22","author":"LV Cooper","year":"2022","unstructured":"Cooper LV, Bandyopadhyay AS, Gumede N, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa[J]. Lancet Infect Dis. 2022;22(2):284\u201394.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"9389_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/risa.13622","volume":"41","author":"DA Kalkowska","year":"2021","unstructured":"Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of outbreak response strategies for 2019\u20132029: impacts of using a novel type 2 oral Poliovirus Vaccine Strain[J]. Risk Anal. 2021;41(2):329\u201348.","journal-title":"Risk Anal"},{"issue":"9","key":"9389_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1716677","volume":"379","author":"IM Blake","year":"2018","unstructured":"Blake IM, Pons-Salort M, Molodecky NA, et al. Type 2 Poliovirus Detection after global withdrawal of trivalent oral Vaccine[J]. N Engl J Med. 2018;379(9):834\u201345.","journal-title":"N Engl J Med"},{"issue":"13","key":"9389_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.vaccine.2018.02.051","volume":"36","author":"AF Saleem","year":"2018","unstructured":"Saleem AF, Yousafzai MT, Mach O, et al. Evaluation of vaccine derived poliovirus type 2 outbreak response options: a randomized controlled trial, Karachi, Pakistan[J]. Vaccine. 2018;36(13):1766\u201371.","journal-title":"Vaccine"},{"issue":"16","key":"9389_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm6916a1","volume":"69","author":"MM Alleman","year":"2020","unstructured":"Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, July 2019-February 2020[J]. MMWR Morb Mortal Wkly Rep. 2020;69(16):489\u201395.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"14","key":"9389_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.15585\/mmwr.mm7214a3","volume":"72","author":"JP Bigouette","year":"2023","unstructured":"Bigouette JP, Henderson E, Mohamed A, Traor\u00e9, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, January 2021-December 2022[J]. MMWR Morb Mortal Wkly Rep. 2023;72(14):366\u201371.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"9389_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.15585\/mmwr.mm7223a1","volume":"72","author":"T Stehling-Ariza","year":"2023","unstructured":"Stehling-Ariza T, Wilkinson AL, Diop OM, et al. Surveillance to Track Progress toward Poliomyelitis Eradication-Worldwide, 2021\u20132022. Morb Mortal Wkly Rep. 2023;72(23):613\u201320.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"07","key":"9389_CR14","first-page":"550","volume":"41","author":"Q Chen Qiang","year":"2021","unstructured":"Chen Qiang Q, Yuhua L, Hongying, et al. Compare the polio antibody level before and after the conversion of inactivated poliovirus vaccine immunization program[J]. Chin J Microbiol Immunol. 2021;41(07):550\u20134.","journal-title":"Chin J Microbiol Immunol"},{"issue":"05","key":"9389_CR15","first-page":"548","volume":"35","author":"Z Yang Xiuhui","year":"2021","unstructured":"Yang Xiuhui Z, Yong Z, Shuangli, et al. To evaluate the neutralizing antibody of poliovirus in children aged\u2009<\u200912 years of Fujian Province[J]. Chin J Experimental Clin Virol. 2021;35(05):548\u201354.","journal-title":"Chin J Experimental Clin Virol"},{"issue":"04","key":"9389_CR16","first-page":"378","volume":"25","author":"Z Wang Qing","year":"2019","unstructured":"Wang Qing Z, Yuanyuan X. Immunogenicity of sequential polio vaccination schedules that use inactivated polio vaccine as the first dose[J]. Chin J Vaccines Immun. 2019;25(04):378\u201382.","journal-title":"Chin J Vaccines Immun"},{"issue":"03","key":"9389_CR17","first-page":"349","volume":"24","author":"S Wen Ning","year":"2018","unstructured":"Wen Ning S, Qiru A, Zhijie, et al. Considerations and suggestions for polio vaccination strategies in China[J]. Chin J Vaccines Immunizations. 2018;24(03):349\u201353.","journal-title":"Chin J Vaccines Immunizations"},{"key":"9389_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","volume":"1387","author":"WC Weldon","year":"2016","unstructured":"Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of Poliovirus Antibodies[J]. Methods Mol Biol. 2016;1387:145\u201376.","journal-title":"Methods Mol Biol"},{"issue":"15","key":"9389_CR19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0264-410X(02)00523-6","volume":"21","author":"DC Parent","year":"2003","unstructured":"Parent DC, I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules[J]. Vaccine. 2003;21(15):1710\u20138.","journal-title":"Vaccine"},{"issue":"5","key":"9389_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa1202541","volume":"368","author":"S Resik","year":"2013","unstructured":"Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J]. N Engl J Med. 2013;368(5):416\u201324.","journal-title":"N Engl J Med"},{"key":"9389_CR21","unstructured":"Geneva: World Health Organization. Considerations for the timing of a single dose of IPV in the routine immunization schedule[EB\/OL]. (2014-06-03)https:\/\/www.who.int\/publications\/i\/item\/WER8901."},{"issue":"14","key":"9389_CR22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","volume":"292","author":"LN Alexander","year":"2004","unstructured":"Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of Poliomyelitis in the United States[J]. JAMA. 2004;292(14):1696\u2013701.","journal-title":"JAMA"},{"issue":"6199","key":"9389_CR23","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1126\/science.1255006","volume":"345","author":"H Jafari","year":"2014","unstructured":"Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India[J]. Science. 2014;345(6199):922\u20135.","journal-title":"Science"},{"issue":"suppl1","key":"9389_CR24","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/cid\/ciy649","volume":"67","author":"JT Gaensbauer","year":"2018","unstructured":"Gaensbauer JT, Gast C, Bandyopadhyay AS, et al. Impact of maternal antibody on the immunogenicity of inactivated Polio Vaccine in infants immunized with bivalent oral Polio Vaccine: implications for the Polio Eradication Endgame[J]. Clin Infect Dis. 2018;67(suppl1):S57\u201365.","journal-title":"Clin Infect Dis"},{"issue":"10040","key":"9389_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","volume":"388","author":"EJ Asturias","year":"2016","unstructured":"Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in latin American infants: an open-label randomised controlled trial[J]. Lancet. 2016;388(10040):158\u201369.","journal-title":"Lancet"},{"issue":"08","key":"9389_CR26","first-page":"1503","volume":"44","author":"GENG Li-na","year":"2017","unstructured":"Li-na GENG, Kai CHU, Guang-wei SUN, et al. Effectiveness of OPV and the influence of maternal anti-poliovirus antibodies on evaluation of OPV in the Chinese infants[J]. Mod Prev Med. 2017;44(08):1503\u20136.","journal-title":"Mod Prev Med"},{"issue":"07","key":"9389_CR27","first-page":"889","volume":"32","author":"CUI Min","year":"2016","unstructured":"Min CUI, De-yu JIANG, Qing HE. Changes in poliovirus neutralizing antibodies among puerperas and infants: a longitudinal study[J]. Chin J Public Health. 2016;32(07):889\u201392.","journal-title":"Chin J Public Health"},{"issue":"2","key":"9389_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0092-1157(83)80031-6","volume":"11","author":"P Albrecht","year":"1983","unstructured":"Albrecht P, Enterline JC, Boone EJ, et al. Poliovirus and Polio antibody assay in HEp-2 and Vero cell cultures[J]. J Biol Stand. 1983;11(2):91\u20137.","journal-title":"J Biol Stand"},{"issue":"7","key":"9389_CR29","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1080\/21645515.2020.1868269","volume":"17","author":"J Xu","year":"2021","unstructured":"Xu J, Wang Q, Kuang S, et al. Immunogenicity of sequential poliovirus vaccination schedules with different strains of Poliomyelitis vaccines in Chongqing, China: a cross-sectional survey[J]. Hum Vaccin Immunother. 2021;17(7):2125\u201331.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09389-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:02:44Z","timestamp":1716886964000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9389"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09389-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human beings in this study were in accordance with the guidelines laid down in the Declaration of Helsinki and approved by the Ethical Committee of Chongqing CDC. Written informed consent was obtained from the legal guardians of the children before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"535"}}